Every 8-K that Hoth Therapeutics Inc (HOTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HOTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HOTH filings page.
Rocket One Inc. filed a Form 8-K to announce the appointment of retired Major General Malcolm B. Frost to its Space and Defense Advisory Board. He will advise on technical development of infrastructure for the orbital economy, including AI computing and memory hardware for space and defense environments.
The press release highlights General Frost’s nearly 40 years of military and national security experience, including 31 years in the U.S. Army and senior operational and communications roles worldwide. Rocket One describes its strategy around nanomagnetic AI chip technology, radiation-tolerant computing, and space and defense applications, while continuing to advance its biotechnology programs through a subsidiary.
Rocket One Inc. disclosed that it has increased the maximum aggregate offering price of its common stock available under its at-the-market sales agreement with H.C. Wainwright & Co., LLC by up to an additional $6,829,000. This ATM program allows the company to issue and sell shares of common stock from time to time into the market. The company also noted that approximately $9,279,067 of common stock had already been sold under this agreement before the increase and that it filed a new prospectus supplement and related legal opinion to cover the expanded capacity.
Rocket One Inc. announced the appointment of Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology. He will guide development of Rocket One’s nanomagnetic AI chip platform, aimed at radiation-tolerant, ultra-low-power computing and memory hardware for space and defense environments.
The filing reiterates Rocket One’s focus on infrastructure for the orbital economy and its exclusive rights to a nanomagnetic matrix multiplier architecture. It also highlights significant risks, including early-stage technology, long development timelines, substantial capital needs, competition, licensing obligations, and regulatory and export-control risks tied to defense and space applications.
Rocket One Inc. increased the maximum aggregate offering price of common stock issuable under its at-the-market Sales Agreement with H.C. Wainwright by up to $2,661,176, and filed a related prospectus supplement along with a legal opinion covering these shares.
The company also announced acceptance into the AMD AI Developer Program, gaining access to cloud resources, tools, and training to support simulation and modeling of its nanomagnetic and spintronic semiconductor technologies for AI, defense, and space applications.
Hoth Therapeutics has created a new subsidiary, Rocket One Inc., which entered into two exclusive license agreements with Virginia Commonwealth University Intellectual Property Foundation. These give Rocket One exclusive, royalty-bearing rights to certain AI semiconductor acceleration and spintronic computing patents and related technical information for commercial use in data centers and artificial intelligence.
The licenses run until the last licensed patent expires or 15 years from the first commercial sale of a covered product or service, whichever is later, and include tiered royalties on net sales, a percentage of sublicensing revenue, minimum annual payments, and reimbursement of patent costs. The company plans to change its name to Rocket One, Inc., pivot its main focus toward AI infrastructure, next-generation semiconductor technologies, and ultra-low-power AI computing, while exploring moving its biotechnology programs into a separate wholly owned subsidiary.
Hoth Therapeutics, Inc. formed a new wholly-owned subsidiary, Rocket One Inc., by filing Articles of Incorporation in Nevada on April 22, 2026. Rocket One is intended to acquire, own and operate space-industry assets, including nano rocket systems used to deploy nanosatellites.
The company characterizes this as part of a potential expansion into the space industry and includes extensive cautionary language that these plans are forward-looking and subject to risks and uncertainties described in its prior SEC filings.
Hoth Therapeutics received a notice from Nasdaq that its common stock no longer meets the exchange’s minimum bid price requirement of $1.00 per share, after trading below that level for 30 consecutive business days ending April 29, 2026.
The company has 180 calendar days, until October 27, 2026, to regain compliance by achieving a closing bid of at least $1.00 for a minimum of 10 consecutive business days. If it qualifies, Hoth may receive an additional 180-day grace period and could appeal any delisting decision. The company plans to monitor its share price and may consider actions such as a reverse stock split to meet Nasdaq listing standards.
Hoth Therapeutics, Inc. is preparing to resume sales of its common stock under its existing At the Market Offering Agreement with H.C. Wainwright & Co., LLC. The company had previously suspended and terminated the prior prospectus supplement and related prospectus, but the underlying Sales Agreement remained in effect.
To restart these at-the-market offerings, Hoth will file a new prospectus supplement to its shelf registration statement on Form S-3 (File No. 333-291566), which was previously declared effective by the SEC on December 4, 2025. The filing also includes a legal opinion and consent from Sheppard, Mullin, Richter & Hampton LLP regarding the validity of the securities to be sold under the Sales Agreement.
Hoth Therapeutics, Inc. entered into a securities purchase agreement to sell 2,857,144 shares of common stock at $0.70 per share, raising approximately $2.0 million in a registered direct offering under its Form S-3 shelf.
In a concurrent private placement, the company issued unregistered warrants to purchase up to 2,857,144 additional shares at $0.85 per share, exercisable six months after issuance for five years and subject to a 4.99% beneficial ownership cap, waivable up to 9.99% with 61 days’ notice. H.C. Wainwright & Co. acted as placement agent, earning cash fees and warrants to buy 142,857 shares at $0.875 per share. Hoth plans to use net proceeds for working capital and general corporate purposes and has suspended use of its existing at-the-market prospectus supplement, with no ATM sales until a new supplement is filed.
Hoth Therapeutics, Inc. filed a Form 8-K to inform the market that it has prepared new presentation materials that management plans to use on and after January 16, 2026. These materials are intended for meetings with U.S. government officials focused on the company’s weight loss drug and broader therapeutics pipeline.
The presentation materials are provided as Exhibit 99.1. Hoth notes that the information in these materials is summary in nature and should be read together with its other SEC filings and public announcements. The company states that the materials speak as of the date of this Form 8-K and, while it may update them in the future, it specifically disclaims any obligation to do so.
Hoth Therapeutics (HOTH) filed a Form 8-K to announce that management has prepared investor presentation materials for use on and after October 17, 2025. The materials are included as Exhibit 99.1 and provide summary information about the company’s operations and performance.
The presentation speaks as of the 8-K date, and the company notes it may update the materials but disclaims any obligation to do so. No transactions, financial results, or new guidance are disclosed in this filing.
Hoth Therapeutics, Inc. disclosed a material agreement: an Employment Agreement between the company and Robb Knie dated August 22, 2025. The filing is an Form 8-K reporting that the employment contract was furnished as an exhibit and the document is signed by Robb Knie in his capacity as Chief Executive Officer. No financial terms, termination provisions, equity awards, or other compensation details appear in the provided text, and there are no financial statements or earnings information included.
Hoth Therapeutics has filed an 8-K report announcing the preparation of new presentation materials that management plans to use for company presentations starting June 24, 2025. The materials are included as Exhibit 99.1 to the Current Report.
Key points from the filing:
- The presentation materials contain summary information that should be considered alongside the company's SEC filings and other public announcements
- The company maintains discretion to update the materials but has no obligation to do so
- Information provided under Item 7.01 and Exhibit 99.1 is furnished rather than "filed" under SEC regulations
- The information will not be incorporated by reference into any Securities Act or Exchange Act filings
The filing was signed by CEO Robb Knie and includes the standard Cover Page Interactive Data File in Inline XBRL format.
Hoth Therapeutics, Inc. ("HOTH") reported that, on June 18, 2025, The Nasdaq Stock Market notified the company that its common stock satisfied the minimum bid price requirement of $1.00 per share for at least ten consecutive business days, thereby restoring full compliance with Nasdaq Listing Rule 5550(a)(2). The company disclosed the notification in this Form 8-K and simultaneously issued a press release, furnished as Exhibit 99.1.